Brentuximab Vedotin News and Research

RSS
Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

FDA accepts SGEN's brentuximab vedotin BLAs for Hodgkin lymphoma, ALCL treatment

FDA accepts SGEN's brentuximab vedotin BLAs for Hodgkin lymphoma, ALCL treatment

Seattle enters second ADC research collaboration agreement with Genmab

Seattle enters second ADC research collaboration agreement with Genmab

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

SGEN, Abbott enter collaboration agreement for ADC products

SGEN, Abbott enter collaboration agreement for ADC products

Millennium, SGEN expand ADC collaboration

Millennium, SGEN expand ADC collaboration

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics prices underwritten public offering of 10,000,000 shares of common stock

Seattle Genetics prices underwritten public offering of 10,000,000 shares of common stock

Seattle Genetics enters ADC collaboration agreement with Pfizer

Seattle Genetics enters ADC collaboration agreement with Pfizer

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010

Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010

Research reveals new standard treatment options for various forms of lymphoma

Research reveals new standard treatment options for various forms of lymphoma

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

SGN-35 drug reduces tumor growth in Hodgkin's lymphoma

SGN-35 drug reduces tumor growth in Hodgkin's lymphoma

New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data

New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data

New antibody with SGN-35 drug produces remission in Hodgkin lymphoma

New antibody with SGN-35 drug produces remission in Hodgkin lymphoma

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

Agensys and Seattle Genetics initiate ASG-5ME phase I clinical trial for castration-resistant prostate cancer

Agensys and Seattle Genetics initiate ASG-5ME phase I clinical trial for castration-resistant prostate cancer

Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.